Improvement of HIV-1 coreceptor tropism prediction by employing selected nucleotide positions of the env gene in a bayesian network classifier

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 7, 2013, Pages 1471-1485

  Díez Fuertes, Francisco ^a   Delgado, Elena ^a   Vega, Yolanda ^a   Fernández García, Aurora ^a   Teresa Cuevas, María ^a   Pinilla, Milagros ^a   García, Valentina ^a   Pérez á lvarez, Lucía ^a   Thomson, Michael M ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bayesian classifier; Maraviroc; Wrapper

Indexed keywords

VIRUS NUCLEOPROTEIN;

ACCURACY; ARTICLE; BAYES THEOREM; CLASSIFIER; COMPUTER MODEL; ENVELOPE GENE; GENOTYPING TECHNIQUE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREDICTOR VARIABLE; SENSITIVITY AND SPECIFICITY; SEQUENCE ALIGNMENT; VIRAL TROPISM;

EID: 84879491746     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt077     Document Type: Article

References (60)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
2. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.
3. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
4. Miedema F, Meyaard L, Koot M, et al. Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev 1994; 140: 35-72.
5. Symons J, van Lelyveld SF, Hoepelman AI, et al. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. J Antimicrob Chemother 2011; 66: 890-5.
6. Trouplin V, Salvatori F, Cappello F, et al. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001; 75: 251-9.
7. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51: 566-75.
8. Raymond S, Delobel P, Mavigner M, et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol 2010; 47: 126-30.
9. McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24: 2517-25.
10. Jensen MA, Li FS, van't Wout AB, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77: 13376-88.
11. Lengauer T, Sander O, Sierra S, et al. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25: 1407-10.
12. Delobel P, Nugeyre MT, Cazabat M, et al. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 2007, 45: 1572-80.
13. Garrido C, Roulet V, Chueca N, et al. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 2008; 46:887-91.
14. Raymond S, Delobel P, Mavigner M, et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008; 22: F11-6.
15. Recordon-Pinson P, SouliéC, Flandre P, et al. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother 2010; 54: 3335-40.
16. Seclén E, Garrido C, González M, del M, et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 2010; 65: 1486-92.
17. Delgado E, Fernández-García A, Vega Y, et al. Evaluation of genotypic tropism prediction tests compared with in vitro co-receptor usage in HIV-1 primary isolates of diverse subtypes. J Antimicrob Chemother 2012; 67: 25-31.
18. Jensen MA, Coetzer M, van't Wout AB, et al. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 2006; 80: 4698-704.
19. Raymond S, Delobel P, Chaix ML, et al. Genotypic prediction of HIV-1 subtype D tropism. Retrovirology 2011; 8: 56.
20. Boyd MT, Simpson GR, Cann AJ, et al. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol 1993; 67: 3649-52.
21. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, et al. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002; 76: 3852-64.
22. Dimonte S, Mercurio F, Svicher V, et al. Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v3 signatures in the regulation of co-receptor usage. Retrovirology 2011; 8: 33.
23. Thielen A, Lengauer T, Swenson LC, et al. Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially. Antivir Ther 2011; 16: 319-28.
24. Huang W, Toma J, Fransen S, et al. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol 2008; 82: 5584-93.
25. Katoh K, Misawa K, Kuma K, et al. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 2002; 30: 3059-66.
26. Stamatakis A, Hoover P, Rougemont J. A rapid bootstrap algorithm for the RAxML Web servers. Syst Biol 2008; 57: 758-71.
27. Miller MA, Holder MT, Vos R, et al. The CIPRES Portals. http://www. phylo.org/sub_sections/portal (23 January 2013, date last accessed).
28. Gnanakaran S, Daniels MG, Bhattacharya T, et al. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol 2010; 6: e1000955.
29. Frank E, Hall M, Trigg L, et al. Data Mining in bioinformatics using Weka. Bioinformatics 2004; 20: 2479-81.
30. Stothard P. Downloads of Stothard research group (align_learn.pl). http://www.ualberta.ca/~stothard/software.html (23 January 2013, date last accessed).
31. Kohavi R, John GH. Wrappers for feature subset selection. Artificial Intelligence 1997; 97: 273-324.
32. Huang CC, Tang M, Zhang MY, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310: 1025-8.
33. Friedman N, Geiger D, Goldszmidt M. Bayesian network classifiers. Machine Learning 1997; 29: 131-63.
34. Minsky M. Steps toward artificial intelligence. In: Feigembaum EA, Feldman J, eds. Computers and Thought. New York: McGraw Hill; 1963: 406-56.
35. Geno2pheno [coreceptor] 2.0. http://coreceptor.bioinf.mpi-inf.mpg.de (23 January 2013, date last accessed).
36. WebPSSM. http://indra.mullins.microbiol.washington.edu/webpssm (23 January 2013, date last accessed).
37. Vandekerckhove LP, Wensing AM, Kaiser R, et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11: 394-407.
38. Fernández-García A, Cuevas MT, Muñoz-Nieto M, et al. Development of a panel of well-characterized human immunodeficiency virus type 1isolates from newly diagnosed patients including acute and recent infections. AIDS Res Hum Retroviruses 2009; 25: 93-102.
39. Cuevas MT, Fernández-García A, Pinilla M, et al. Short communication: Biological and genetic characterization of HIV type 1 subtype B and nonsubtype B transmitted viruses: usefulness for vaccine candidate assessment. AIDS Res Hum Retroviruses 2010; 26: 1019-25.
40. Revilla A, Delgado E, Christian EC, et al. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F. AIDS Res Hum Retroviruses 2011; 27: 889-901.
41. Dettin M, Ferranti P, Scarinci C, et al. Is the V3 loop involved in HIV binding to CD4? Biochemistry 2003; 42: 9007-12.
42. Kwong PD,Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59.
43. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393: 705-11.
44. LaBonte JA, Babcock GJ, Patel T, et al. Blockade of HIV-1 infection of New World monkey cells occurs primarily at the stage of virus entry. J Exp Med 2002; 196: 431-45.
45. González-Serna A, McGovern RA, Harrigan PR, et al. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods. Antimicrob Agents Chemother 2012; 56: 1202-7.
46. Hemelaar J, Gouws E, Ghys PD, et al. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25: 679-89.
47. Thomson MM, Nájera R. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev 2005; 7: 210-24.
48. Thielen A, Sichtig N, Kaiser R, et al. Improved prediction of HIV-1 coreceptor usage with sequence information from the second hypervariable loop of gp120. J Infect Dis 2010; 202: 1435-43.
49. Rosen CA, Terwilliger E, Dayton A, et al. Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Nat Acad Sci U S A 1998; 85: 2071-5.
50. Daly TJ, Cook KS, Gray GS, et al. Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature 1989; 342: 816-9.
51. Hadzopoulou-Cladaras M, Felber BK, Cladaras C, et al. The Rev (Trs/Art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J Virol 1989; 63: 1265-74.
52. Cooper DA, Lange JM. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. Lancet Infect Dis 2004; 4: 426-36.
53. Kliger Y, Peisajovich SG, Blumenthal R, et al. Membrane-induced conformational change during the activation of HIV-1 gp41. J Mol Biol 2000; 301: 905-14.
54. Sing T, Low AJ, Beerenwinkel N, et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007; 12: 1097-106.
55. Svicher V, Alteri C, Artese A, et al. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. Antivir Ther 2011; 16: 1035-45.
56. Schuurman R, Demeter L, Reichelderfer P, et al. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999; 37: 2291-6.
57. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43: 406-13.
58. McGovern R, SymonsJ, PoonAet al. Longitudinal 'deep' sequenceanalysis of dual/mixed infected patients treated with maraviroc demonstrates rapid selection for X4-tropic virus with extremely low FPR. In: Abstracts of the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Abstract A97, p. 76. Los Cabos, Mexico, 2011.
59. Santoro MM, Armenia D, Fabeni L, et al. The lowest X4 Geno2pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. Clin Microbiol Infect 2012; 18: E289-98.
60. Salazar-Gonzalez JF, Bailes E, Pham KT, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82: 3952-70.